# Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors

> **NCT05886868** · PHASE1 · UNKNOWN · sponsor: **Shanghai Best-Link Bioscience, LLC** · enrollment: 66 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** BL0020

## Key facts

- **NCT ID:** NCT05886868
- **Lead sponsor:** Shanghai Best-Link Bioscience, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-10-24
- **Primary completion:** 2024-07
- **Final completion:** 2025-02
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2023-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05886868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05886868, "Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05886868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*